Bacillus subtilis CU1 is a recently described probiotic strain with beneficial effects on immune health in elderly subjects. The following work describes a series of studies supporting the safety of the strain for use as an ingredient in food and supplement preparations. Using a combination of 16S rDNA and gyrB nucleotide analyses, the species was identified as a member of the Bacillus subtilis complex (B. subtilis subsp. spizizenii). Further characterization of the organism at the strain level was achieved using random amplified polymorphic DNA polymerase chain reaction (RAPD PCR) and pulsed field gel electrophoresis (PFGE) analyses. B. subtilis CU1 did not demonstrate antibiotic resistance greater than existing regulatory cutoffs against clinically important antibiotics, did not induce hemolysis or produce surfactant factors, and was absent of toxigenic activity in vitro. Use of B. subtilis CU1 as a probiotic has recently been evaluated in a 16-week randomized, double-blind, placebo-controlled, parallel-arm study, in which 2 Â 10 9 spores per day of B. subtilis CU1 were administered for a total 40 days to healthy elderly subjects (4 consumption periods of 10 days separated by 18-day washouts). This work describes safety related endpoints not previously reported. B. subtilis CU1 was safe and well-tolerated in the clinical subjects without undesirable physiological effects on markers of liver and kidney function, complete blood counts, hemodynamic parameters, and vital signs.
Introduction
Probiotics are defined as live microorganisms that when ingested in sufficient quantities provide a health benefit to the host (FAO/WHO, 2001) . Current probiotic preparations on the market are largely represented by species from the Lactobacillus and Bifidobacterium genera; however probiotic species from Streptococcus, Enterococcus and other bacterial species such as Clostridium butyricum and Escherichia coli, and yeast (Saccharomyces cerevisiae) have a history of safe consumption as probiotic ingredients (Sanders et al., 2010; Kanai et al., 2015) . The use of Bacillus species as probiotics has gained recent interest due to the fact that spore-forming bacteria, in contrast to vegetative cells, possess a number of interesting characteristics. Specifically, spores are extremely resistant to heat and desiccation allowing Bacillus probiotics to be stored at room temperature as dried powdered formulations for extended periods. Secondly, a wide range of pH stability allows spores to survive passage through the low pH gastric barrier of the stomach resulting in the delivery of high numbers of viable microbes to the lower intestine (Cutting, 2011) . Indirect introduction of Bacillus species to the food supply has occurred for decades through their use in animal production as feed additives (e.g., B. subtilis) without evidence of untoward effects on humans (Hong et al., 2005; EFSA, 2014) . Probiotic preparations containing Bacillus species (e.g., B. clausii, B. coagulans, B. subtilis) have been reported to be effective in preventing gastrointestinal disorders such as childhood diarrhea when used prophylactically (Hong et al., 2005) , decreasing the duration of respiratory infections in children (Marseglia et al., 2007) , and overcoming symptoms associated with irritable bowel syndrome (Tompkins et al., 2010) . Bacillus probiotics are currently more widely marketed in South East Asia than in Europe and the United States (U.S.), but interest in the West is increasing rapidly (Cutting, 2011) .
Bacillus subtilis is ubiquitous in the environment and can be isolated from water, soil, air, and decomposing plant matter. Likely as an indirect result of consuming plant matter, numerous Bacillus species have also been found in the gastrointestinal tract of animals (Tam et al., 2006; Hong et al., 2009 ). The species is an important source of enzymes used for food, animal feed, and other industrial applications (Schallmey et al., 2004; Health Canada, 2016) , and several proprietary strains have been marketed as probiotic supplements for human consumption in Asia, Europe, and the U.S (Cutting, 2011) . The mechanism by which Bacillus spores, specifically those of the B. subtilis species, act as probiotics is not well understood. It is hypothesized that B. subtilis exerts beneficial probiotic effects, including the production of antimicrobials, stimulation of the immune system, and overall enhancement of gut microflora (Hoa et al., 2001; Casula and Cutting, 2002; Tam et al., 2006; Dudonn e et al., 2015) . Members of B. subtilis also have an established history of use in the preparation of several traditional fermented foods that have a long history of consumption in Southeast Asia (e.g., natto) and Africa (e.g., ogiri) (Wang and Fung, 1996) , and consumption of these foods is believed to be associated with numerous health benefits, such as enhanced immunity, reduced bone loss in post-menopausal women, and anti-allergy effects (Ouoba et al., 2004; Ikeda et al., 2006; Shurtleff, 2012) .
Recently, a newly identified strain of B. subtilis, CU1 (CNCM I-2745), has been described as a probiotic in mice (Dudonn e et al., 2015) and an effective probiotic in healthy elderly subjects (Lefevre et al., 2015) . In the clinical study, intermittent consumption of B. subtilis CU1 was found to decrease the occurrence of infectious episodes in healthy free-living elderly subjects during a period of common infectious disease (i.e., the winter season in France). The authors attributed these effects to the ability of B. subtilis CU1 to enhance systemic as well as intestinal and respiratory mucosal immune responses, as indicated by the increased concentrations of fecal and salivary secretory IgA and serum interferon-gamma. The safety of this probiotic was assessed by Lefevre et al. (2015) , but full details of the safety data were not reported.
To determine if a new microbial strain intended for use as a probiotic is safe for human consumption, a number of regulatory guidelines and scientific decision trees have been published to assist with this task. The European Food Safety Authority (EFSA) has issued guidelines for the safety assessment of select microorganisms that: a) have an extensive history of use in the food industry, and; b) for which a wide body of evidence exists characterizing members of the genus (EFSA, 2007) . The Qualified Presumption of Safety (QPS) approach, as it is referred to, has been used by EFSA to evaluate various species of the Bacillus genus and has specifically granted QPS status to the B. subtilis species (EFSA, 2015) . Therefore, to satisfy QPS status, any new B. subtilis strain must: i) be identified at the strain and species level; ii) be absent of transferable antimicrobial resistances (EFSA, 2012); and iii) lack toxigenic activity. The Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food has also published guidelines for the Evaluation of Probiotics in Food (FAO/WHO, 2002) . Within these guidelines, safety considerations outline a number of recommended safety tests for probiotics in vitro, similar to the QPS recommendations, but also highlight the importance of conducting human consumption studies to determine if the probiotic leads to the induction of any undesirable physiological effects. Taking these regulatory guidelines into consideration, Pariza et al. (2015) recently published a decision tree that summarizes in a step-wise manner how to conduct thorough safety assessments of microbial cultures intended for human and animal consumption. The intent of this present work was to evaluate the safety of B. subtilis CU1 for human consumption. Studies characterizing the genomic identity of the strain at the species/subspecies level using 16S ribosomal DNA and gyrase B (gyrB) nucleotide sequencing were conducted. Unique DNA fingerprints for strain identification of the organism were obtained using random amplified polymorphic DNA (RAPD) polymerase chain reaction (PCR) and pulsed field gel electrophoresis (PFGE) analyses. The broth microdilution assay was used to evaluate resistance against eight clinically important antibiotics, and in vitro studies evaluating the capacity of the strain for synthesis of toxic secondary metabolites with hemolysis and/or cytotoxic potential were conducted. Human safety endpoints not previously reported by Lefevre et al. (2015) , including analyses of adverse event reporting, outcomes of clinical chemistry and hematological analyses, and measures of vital status are presented herein. Safety evaluations, both in vitro and in the clinic, demonstrate that B. subtilis CU1 can be classified as a non-pathogenic and non-toxicogenic strain of B. subtilis, and was safe and well-tolerated during repeated consumption in healthy elderly subjects at 2 Â 10 9 spores/day for a total of 40 days. B. subtilis CU1 was therefore considered safe and suitable for use as a probiotic ingredient. United States strains were also used. Bacillus strains were routinely grown aerobically in Mueller Hinton (MH) broth (Becton Dickinson (BD), Le Pont de Claix, France) for 24e48 h, at 30 C or 37 C in a rotary shaker (150 rpm), or in MH broth supplemented with 1.5% (w/v) agar for plates. To assess the toxigenic activity of the supernatants, Bacillus strains were also grown in Luria-Bertani (LB) broth (BD). C. difficile was grown in Brain Heart Infusion (BHI) broth (BD) supplemented with yeast extract 1% (w/v) for 3 days at 37 C under anaerobic conditions. Culture supernatants were harvested by centrifugation at 4 C (10,000g, 5 min), neutralized, and then filtered (0.2 mm, cellulose acetate membrane).
Materials
Staphylococcus aureus ATCC 29213 was used as a control in the broth micro-dilution method. It was grown aerobically at 37 C and frozen stock cultures were stored at À80 C in MH or BHI broth supplemented with 18% glycerol (v/v).
Species and strain identification

Nucleotide sequence analyses
Genomic DNA from Bacillus strains was prepared as described previously (Hyronimus et al., 1998) . Molecular species identification of B. subtilis CU1 was assessed by partial sequencing of the ribosomal 16S DNA gene (1312 base pairs) and gyrB sequencing (551 base pairs). Ribosomal 16S RNA was amplified and sequenced using the Fpnal (5'-AAGTCGAACGGGGTGTTTA-3') and RPna2 (5'-CAAACCCGAAGCCGGCTG-3') primers according to the method described by Chevrot et al. (2008) . GyrB was amplified using the UP-1 and UP-2r primers (Eurofins Genomics, Ebersberg, Germany), purified by the NucleoSpin ® Gel and PCR Clean-up kit manufactured by Macherey-Nagel (Duren, Germany), and sequenced using the degenerate UP-1S and UP-2Sr primers and an ABI 3500 genetic analyzer (Applied Biosystems Inc., Life Technologies SAS, Saint Aubin, France). The primer sequences used for gyrB amplification (UP-1 and UP-2r) and sequencing (UP-1S and UP-2Sr) were the same as reported in Yamamoto and Harayama (1995) . BLAST analyses were conducted to compare the resulting 16S rDNA and gyrB sequences for B. subtilis CU1 to other B. subtilis strains using the National Center for Biotechnology Information (NCBI) nucleotide database. The B. subtilis CU1 genome was assembled using the bioinformatics software Velvet [version 1.2.10] that operates based upon de novo assembly of reads without any a priori with respect to the organism being studied (Zerbino and Birney, 2008) . A script was prepared to allow for testing of k-mers from 15 to 43 base pairs at 2-base pair intervals. This script generated 93 contigs ranging from 350 to 450,000 base pairs. This Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank under the accession MOOX00000000. The version described in this paper is version MOOX01000000. Following this read assembly, BLAST version 2.2.26 was employed to survey the genome for genes associated with conferring antibiotic (ermA, ermB, ermC, cfr, tetA, tetK, tetL, tetP, tetV, qnrA, qnrB, qnrD, qnrS, parC, parE, gyrA, gyrB, aac, rpoB, msrA, vga, vgB, strA, strB, aphA1, van A, vanB, vanS, vanW) or multidrug resistance (mdtA, mdtB, mdtC, mdtD, mdtE), as well as genes implicated in biogenic amine (hdc, tyrA, tyrB) or enterotoxin (cytK, bceT, hblA, hblB, hblC, hblD, nheA, nheB, nheC) production.
Random amplified polymorphic DNA (RAPD) PCR
RAPD PCR analysis of B. subtilis CU1 was conducted according to the method described by Pinchuk et al. (2002) . Three 10-mer primers OPA3 (5'-AGTCAGCCAC -3'), OPL12 (5'-GGGCGGTACT -3'), and OPH8 (5'-GAAACACCCC-3') (Bioprobe, Montrevils-sous-Bois, France), were utilized for random amplification of DNA segments using a thermal cycler PTC-200 (MJ Research, Ramsey, U.S.).
B. subtilis CU1 was compared to 13 other Bacillus strains, including some typical commercial probiotic strains. RAPD amplifications were repeated at least 3 times for each primer.
Pulsed field gel electrophoresis (PFGE)
PFGE analysis was performed according to a protocol adapted from Marten et al. (2000) combined with the electrophoresis equipment manufacturer recommendations. Bacillus cells grown in LB medium without yeast extract were removed from early exponential phase culture, washed with SE buffer (50 mM EDTA, 100 mM Tris-HCl pH 7.2, 20 mM NaCl), and suspended in SE buffer at a concentration of 2 Â 10 9 cells/mL. Cells were incorporated into low melting agarose plugs (Bio-Rad, Richmond, U.S.). To disrupt cells, the plugs were incubated in different lysis buffers as described by Marten et al. (2000) . For DNA restriction, the plugs were preincubated in restriction SfiI buffer before adding in 30 units of the restriction enzyme SfiI (Thermo Scientific Fermentas, UK) and incubated overnight. Plugs were inserted into the wells of a 1% agarose certified pulsed field gel (Bio-Rad) and digested chromosomal DNA was separated by PFGE using a FIGE Mapper Electrophoresis system (Bio-Rad). Electrophoresis was conducted with a forward voltage of 180 V and a reverse voltage of 120 V for 20 h at ambient temperature with a linear switch time ramp of 0.4e3.5 ms to inverse pulse. A 5 kb ladder from Bio-Rad was used as molecular marker and the assay was repeated twice for each strain tested.
Antibiotic resistance testing
The susceptibility of B. subtilis CU1 to 8 clinically important antibiotics [chloramphenicol, clindamycin, erythromycin, gentamicin, kanamycin, streptomycin, tetracycline, and vancomycin: selected based on the EFSA guidelines for testing antimicrobial susceptibility of the Bacillus species (EFSA, 2012)] was conducted using the broth micro-dilution method based on the method described for Lactobacillus (ISO 10932:2010) . Acquired resistance was established using cut-off values reported within the EFSA guidance for the assessment of bacterial antimicrobial susceptibility (EFSA, 2012). B. subtilis CU1 was grown in 20 mL MH medium under agitation for 24 h at 37 C. Cultures were diluted with MH medium to a concentration of 1 Â 10 6 colony forming units (CFU)/ mL and 100 mL of this suspension was added to the wells of a 96-well plate. S. aureus ATCC 29213 was used as a quality control strain for the assay. Antibiotics were diluted serially in MH medium from a starting concentration of 512-1 mg/L and 100 mL of each concentration was added to the wells containing bacterial culture.
Plates were incubated for 48 h at 37 C and the minimum inhibitory concentration (MIC) for each antibiotic was determined as the lowest antibiotic concentration inhibiting bacterial growth (i.e., absence of turbidity). B. subtilis CU1 growth was controlled in plates using MH medium without the addition of antibiotics (presence of turbidity) whereas negative control wells contained antibiotics supplemented with MH medium but the bacterial strain was not inoculated (absence of turbidity). All experiments were conducted twice.
Assessment of hemolytic and cytotoxic activity
The hemolytic activity of B. subtilis CU1 was tested according to the method described by Promdonkoy and Ellar (2003) . B. subtilis CU1 and B. cereus ATCC 14579 were grown in LB and MH liquid media at 30 and 37 C and cell-free supernatants were collected by centrifugation. CU1 supernatants were obtained from 3 independent cultures and were tested in triplicate. Human blood obtained from healthy volunteers (EFS Aquitaine, Bordeaux Blood Bank, France) was centrifuged (2000g, 10 min) to isolate the erythrocytes. Cell-free supernatants (100 mL) and erythrocytes in PBS (100 mL, 2.5 Â 10 8 cells/mL) were combined in the wells of a 96-well polystyrene plate. After 3 h of incubation at room temperature, total released hemoglobin was measured at 415 nm using a Nanodrop 1000 spectrophotometer (Thermo Scientific, Waltham, U.S.). Sodium dodecyl sulfate (SDS, 3.47 mM) and B. cereus 14579 supernatants were used as positive controls and LB and MH broth were used as negative controls. Surfactant activity of B. subtilis CU1 was assessed using the qualitative drop-collapse test described by Bodour and Miller-Maie (1998) . B. subtilis CU1 grown at 37 C for 72 h in LB and MH solid media, as well as in the same liquid media, was tested for biosurfactant production by placing a small drop (5 mL) of each cell suspension (one colony suspended in 150 mL of demineralized water), or 5 mL of culture supernatants, in wells coated with 2 mL of oil (Elf 700 Diesel 10W40). Crystal violet dye (1 mL) was added to each sample after 1 min to assist with visualizing the drops with the aid of a magnifying glass. B. subtilis 13 GR, a surfactin producing strain, was used as a positive control, and distilled water as a negative control. The result was considered positive when the drop was flat and negative when drops were rounded, indicating a lack of biosurfactant production. Three independent cultures of the CU1 strain for each culture media (LB and MH) were analyzed in triplicate.
Cytotoxic activity of B. subtilis CU1 was evaluated on Vero cells (Sigma-Aldrich, Lyon, France) by analyzing cell detachment as previously reported (Saotome et al., 1989) . Vero cells, a wellestablished cell line used extensively for cytotoxicity testing, were grown in Dulbecco's Modified Eagle's Medium (DMEM) (SigmaAldrich), supplemented with 10% (v/v) of heat-inactivated fetal bovine serum (Gibco, Thermo Scientific), 0.5% (v/v) of penicillin and streptomycin (Sigma-Aldrich), and 1% (v/v) of nonessential amino acids (Sigma-Aldrich). A cellular suspension of 10 5 cells was seeded into 12-well culture plates containing 2 mL of cell culture medium and incubated until confluence. B. subtilis CU1 supernatants (100 mL) from LB and MH media overnight cultures grown at 30 and 37 C were added to the Vero cells and incubated for 3 h at 37 C. Cells were stained with crystal violet solution as described by Lefevre et al. (2015) to measure cell detachment. Absorbance was measured at 650 nm and the percentage of attached cells was calculated as 100 Â (A/Ac), where A is the absorbance of treated cells and Ac is the absorbance of untreated control cells. B. cereus 14579 and C. difficile CD VPI 10463, bacteria that produce cytotoxic factors, were used as positive controls, and MH medium was used as a negative control. CU1 supernatants were obtained from 3 independent cultures and the cytotoxicity test was repeated 3 times.
2.5. Human safety assessment 2.5.1. Subjects B. subtilis CU1 consumption was recently assessed in healthy free-living elderly subjects in a randomized, double-blind, placebocontrolled, parallel-arm clinical study (Lefevre et al., 2015) . Briefly, 100 elderly subjects (60e74 years of age) were divided into placebo (39 females, 11 males; n ¼ 50) and probiotic (40 females, 10 males; n ¼ 50) groups. The mean age of the placebo and probiotic groups was 63.0 and 63.3 years, respectively. Consumption of dietary supplements and probiotics was not allowed for 2 and 1 months leading up to the start of the study, respectively, as well as for the duration of the study.
Experimental design
The study duration was 16 weeks in total, comprised of four consumption periods of 10 days each, each separated by 18-day washout periods. During the consumption period, subjects in the probiotic group (n ¼ 50) consumed one B. subtilis CU1 capsule per day containing 2 Â 10 9 spores of B. subtilis CU1 (Lesaffre Human Care, Marcq en Baroeul, France). The probiotic capsules contained the active ingredient (95% B. subtilis spores and 5% B. subtilis vegetative cells) mixed with the following excipients: maltodextrin DE14, dicalcic phosphate, magnesium stearate, and colloidal silica. Participants in the placebo group (n ¼ 50) were supplied with capsules containing only the excipient mix and all subjects were instructed to consume one capsule daily, 40 min before eating breakfast. Full study details and evaluation of the ability of B. subtilis CU1 to stimulate the immune system and promote resistance to common infectious diseases were previously reported by Lefevre et al. (2015) . 
Safety assessment
A number of safety parameters were also evaluated during the trial, including the occurrence of adverse events, measurement of hematology, clinical chemistry, and hemodynamic parameters; however, the results of these analyses were not previously published by Lefevre et al. (2015) . Therefore the methods and results of these assessments are reported herein. The occurrence of adverse events was documented by the investigators in the case report forms for each subject. The association of each adverse event with study participation was ranked by the investigators as not likely, possible, likely, or certain, and the intensity of each adverse event was classified by the investigators as mild (no restriction of daily activities), moderate (partial restriction of daily activities), or severe (inability to achieve daily activities). Blood was collected into EDTA-coated tubes and serum collection tubes at baseline (1e2 weeks before the start of the study) and at study endpoint (week 16) for complete blood counts and evaluation of liver and kidney markers. Whole blood was analyzed using a CELL-DYN 3200 SL hematology analyzer (Abbott Laboratories, Taguig City, Philippines) to obtain standard complete blood count data. Clinical chemistry parameters were evaluated in the serum samples using a Roche Hitachi 911 chemistry analyzer according to the Roche Diagnostics (Mannheim, Germany) kit protocols as follows: alanine transaminase (ALT), UV test; aspartate transaminase (AST), UV test; creatinine, enzymatic colorimetric test; gamma-glutamyltransferase (GGT), enzymatic colorimetric test; urea, kinetic UV test. Hemodynamic parameters, including arterial pressure and heart rate, were evaluated on the first day of the study (prior to probiotic consumption), halfway through the study (day 56/week 8), and at the end of the study (day 112/week 16). 
Statistical analyses
In vitro studies
Statistical analysis of all in vitro data was performed using GraphPad Prism ® Software version 6.0 for Windows (San Diego, U.S.). Two-tailed Student's t-tests were performed for comparisons between the different groups.
Human study
As outlined in the original study plan (Lefevre et al., 2015) , all clinical data were analyzed using SAS ® software version 9.1.3 Service Pack 4 (SAS Institute Inc., Cary, U.S.) and results were expressed as mean ± SD. Statistical significance was set at P < 0.05. The number of subjects with at least one adverse effect, the association of adverse events with study participation, and the severity of adverse events were compared between the probiotic and placebo groups using the chi-square test or Fisher's exact test.
Results
Species and strain identification
A total of 1312 nucleotides of 16S rDNA of B. subtilis CU1 were sequenced. The obtained sequence was compared to the 16S rDNA sequences deposited in the NCBI nucleotide database, and strong homology was found between B. subtilis CU1 and Bacillus subtilis subsp. subtilis and Bacillus subtilis subsp. spizizenii (Table 1) . Molecular identification of B. subtilis CU1 to a species level was determined by sequencing gyrB (551 base pairs), and when compared to the NCBI nucleotide database, characterization of the strain at the subspecies level as Bacillus subtilis subspecies spizizenii was suggested by the high homology to two spizizenii isolates (Table 1) .
Characterization of B. subtilis CU1 at the strain level was conducted using RAPD PCR analysis with three different primers. The RAPD method was sufficiently robust to distinguish the strain from 13 other Bacillus reference strains and this differentiation was most clear with the OPA3 and OPL12 primers (Fig. 1A and B) . The OPH8 primer did not generate as unique a banding pattern for B. subtilis CU1 (Fig. 1C) . Similarly, the PFGE profile of B. subtilis CU1 (lanes 2 & 3, Fig. 2 ) was clearly distinguishable from five commercially available probiotic strains of B. subtilis (lanes 1, 4e7, Fig. 2 ) and distinct banding patterns were observed for B. subtilis CU1 relative to B. licheniformis and B. clausii (lanes 8 & 9, Fig. 2 ). The molecular typing methods used showed that strain-specific profiles could be obtained for the B. subtilis CU1 strain. Two different batches of B. subtilis CU1 that were produced in consecutive years were included in the RAPD and PFGE analyses (see lanes b & c of Fig. 1 and lanes 2 & 3 of Fig. 2 ) and were determined to be identical in their genotypic analyses. The results for the RAPD and PFGE analyses shown in Figs. 1 and 2 are representative of multiple evaluations. 
Antibiotic resistance testing
MICs for each antibiotic are shown in Table 2 . The MIC results for the S. aureus ATCC 29213 reference control strain were in-line with the quality control ranges set by the Clinical and Laboratory Standards Institute (CLSI, 2011). The MICs determined for B. subtilis CU1 were compared to the Bacillus break points published by EFSA (2012) and all concentrations were less than or equal to their respective break point values.
Assessment of toxigenic activity
The toxigenic potential of B. subtilis CU1 was evaluated by assessing its hemolytic, surfactant, and cytotoxic activity in vitro (Table 3) . Hemolytic activity was evaluated on human erythrocytes by the addition of cell-free supernatants to fresh, viable erythrocyte cultures. B. subtilis CU1 cell-free supernatants (from LB or MH media cultured at 30 or 37 C) did not induce hemolysis of erythrocytes. When erythrocytes were incubated with cell-free supernatant from B. cereus 14579 cultures or SDS, high levels of hemoglobin were released from the erythrocytes under all experimental conditions (Fig. 3A, Table 3 ).
The surfactant activity of B. subtilis CU1 was assessed by the qualitative drop-collapse method. B. subtilis 13 GR cultures (positive control) grown in liquid LB and MH media produced significant surfactant activity, and some dispersion (slightly spread out) was also observed when this strain was grown on solid LB medium (data not shown). Conversely, B. subtilis CU1 grown on solid LB and MH media, as well as liquid LB and MH media, did not produce any metabolites with biosurfactant properties; the drops remained beaded in all of the test wells and were visually comparable to the negative control wells (Table 3 ).
The cytotoxicity of B. subtilis CU1 supernatant was tested on Vero cells using the crystal violet staining assay to assess cellular detachment as a measure of viability. Cytotoxicity was observed to Vero cells exposed to the cell-free supernatants of the positive controls B. cereus 14579 and C. difficile CD VPI, as indicated by the significant reduction in OD values. Vero cells exposed to the cellfree supernatant of B. subtilis CU1 grown in liquid media (LB and MH) at two different temperatures (30 and 37 C) remained viable, and no difference in OD values relative to the negative control values was observed (Fig. 3B, Table 3 ). Results shown in Fig. 3 are representative of multiple evaluations.
Clinical safety assessment
Over 16 weeks of B. subtilis CU1 consumption (2 Â 10 9 spores/ day for 40 days in total), no statistically significant trends in the number of subjects experiencing at least one adverse event were observed between the probiotic and control groups (51.6% of the probiotic group, 48.4% of the placebo group, P ¼ 0.68) ( Table 4 ). The likelihood of the adverse events being associated with study participation, ranked as not likely, possibly, likely, or certainly related, was no different between the placebo and B. subtilis CU1 groups when assessed based on total events (P ¼ 0.70) as well as based on only 1 event per subject (P ¼ 0.36). As outlined in Table 5 , 3 events in the treatment group were possibly associated with participation in the study (2 incidents of nasal obstruction episodes in the same subject and one report of headache in another subject), and one event was likely related (mild pain for about 10 min after test capsule consumption) but remained an isolated event. One case of vasovagal episode during blood sampling was certainly associated with participation in the study, but was not related to test article consumption. In the placebo group, only one event, a headache that appeared minutes after taking the test product and disappeared over the course of the day, was possibly related to study participation. The majority of adverse events in both placebo (98.81%) and probiotic (95.37%) groups were not related to participation in the study (Table 4) . The intensity of each adverse event was classified as mild, moderate, or severe, and the summary of adverse events by intensity is provided in Table 6 . Statistical analysis indicated that adverse events in the probiotic group were significantly more intense when compared to placebo (P ¼ 0.01) ( Table 4 ). This association was likely due to the fact that 2 subjects in the probiotic group with known histories of migraines experienced multiple episodes during the study. Migraines reported by these 2 subjects, unrelated to treatment, accounted for 40% of the total adverse events in the probiotic group classified as moderate. The first Fig. 3 . Assessing the toxigenic activity of B. subtilis CU1. B. subtilis CU1 (CU1) was grown in LB or MH broth at 30 C and 37 C. A) Hemolytic activity testing. B. subtilis CU1 cell-free supernatants were incubated with human erythrocytes for 3 h. Bars represent hemoglobin release measured by absorbance at 415 nm. Positive controls: SDS and B. cereus 14579 (Bc). B) Cytotoxic activity testing. B. subtilis CU1 cell-free supernatants were added to wells containing Vero cells and incubated for 2 h at 37 C. Cells were stained with crystal violet dye and absorbance was measured at 650 nm. Positive controls: B. cereus 14579 (Bc) and C. difficile VPI (Cd) supernatants; negative control: MH medium. All results are the average of 3 values from independent experiments ± SD, where (***) indicates a significant difference compared to the corresponding control (P < 0.001). subject reported 16 migraine episodes, of which 2 were classified as mildly intense and 14 were moderate. The second subject experienced 10 migraine episodes that were all classified as moderately intense. One subject in the placebo group with a known history of migraines experienced 9 migraines during the study, of which 8 were classified as mildly intense and one was moderate, all unrelated to treatment. All adverse events related to treatment in both placebo (1 event) and probiotic groups (5 events) were mild in severity, and based on 1 event per subject of highest severity, no statistical difference was found between the 2 groups with respect to the mild events being related to treatment (P ¼ 0.34) ( Table 4 ). All moderate events were unrelated to treatment and no severe events occurred during the study.
One serious adverse event occurred during the study, unrelated to study participation, where one subject in the placebo group required hospitalization for a hallux valgus foot deformity. The following infections were documented during the study period, none of which were attributed to participation in the study: one dental infection, one cutaneous infection, one case of genital herpes, and one case of ungual mycosis occurred in the probiotic group; one case of labial herpes and one case of panaritium occurred in the placebo group.
The markers of liver and kidney function (ALT, AST, GGT, creatinine, and urea) measured at baseline and week 16 were not significantly different between the probiotic and placebo groups at either time point. Similarly, results of the complete blood count were not significantly different between the groups at baseline or week 16. Hemodynamic parameters (arterial pressure and heart rate), likewise, did not show any significant differences between the two groups at baseline, week 8, or week 16, nor any pathologic variation (Table 7) .
Discussion and conclusion
B. subtilis CU1 is intended for use as a probiotic and therefore the safety of this ingredient was evaluated based upon the regulatory guidelines published by EFSA (QPS) and the Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food. The safety assessment included a series of in vitro experiments to characterize the new microbial strain and assess its toxigenic potential, followed by a randomized, doubleblind, placebo-controlled, parallel-arm clinical study.
First, to satisfy QPS status defined by EFSA for the B. subtilis species, B. subtilis CU1 was identified at the species and strain level using a combination of genomic testing techniques. The B. subtilis species complex consists of an assemblage of closely related species and it has been long established that the use of phenotypic, biochemical, and 16S rDNA sequencing are insufficient for discriminating between species within this complex (Rooney et al., 2009) . Partial sequencing of the ribosomal 16S DNA, up to a maximum of 1312 base pairs, and comparison of this sequence with other Bacillus strains showed strong homology with several Bacillus species belonging to the B. subtilis group (!99%). Using nucleotide sequence analyses of gyrB, Wang and colleagues have identified gyrB as a secondary target for taxonomic identification of members of the B. subtilis complex (Wang et al., 2007) . A sequence homology of 97% and 95% was observed for B. subtilis CU1 gyrB relative to respective gyrB sequences of Bacillus subtilis subsp. spizizenii and B. subtilis subsp. subtilis identified within the NCBI database. As reported by Wang et al. (2007) , strains with 95.5e100% identity with the gyrB sequence display high DNA-DNA relatedness suggesting the strains are conspecific. Strains with 93e95% similarity in the gryB sequence typically exhibit DNA-DNA relatedness of 60e70% indicating grouping at the subspecies level. Therefore, based on the results of the 16S rDNA and gryB nucleotide analyses, B. subtilis CU1 can be identified at the subspecies level as B. subtilis subsp. spizizenii. Identification at the strain level is an important element of the safety assessment of a microorganism as it establishes the identity of the strain of interest in a similar manner that a specification is used to characterize chemical ingredients, and can be used for quality control, establishing genomic stability, and post-market surveillance purposes. Effective discrimination of a probiotic at the strain level is also critical for confirming the identity of microbial test articles used in safety studies. In the case of B. subtilis CU1, strain characterization was effectively achieved through RAPD PCR analysis that produced consistent DNA fingerprints unique to the B. subtilis CU1 strain. Thus, RAPD can be used as a fast method to discriminate between probiotic strains, for example, when enumerating colonies of a probiotic strain present in fecal samples (Lefevre et al., 2015) , but nevertheless, has its disadvantages as inter-laboratory reproducibility is characteristically low (Sabat et al., 2013) . On the other hand, PFGE is often considered the gold standard of molecular typing methods, presenting a high degree of reproducibility and resolving power, and SfiI is the most frequently used enzyme in conventional probiotic Bacillus PFGE protocols (De Baets et al., 2009) . In this study, PFGE analysis of B. subtilis CU1 using SfiI resulted in a unique DNA pattern, and moreover, when two independent production batches generated in consecutive years were tested, one identical pattern was obtained. Therefore, PFGE may be the method of choice to control industrial probiotic production and for unambiguous B. subtilis CU1 strain discrimination.
It is generally recognized that all microorganisms used as direct food ingredients should be evaluated for the potential to harbor potentially transferable acquired antibiotic resistance traits. The guidelines set by the EFSA FEEDAP Panel in 2012 (EFSA, 2012 suggest that the Bacillus species should be tested against the following antibiotics: vancomycin, gentamycin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol. We were able to demonstrate that B. subtilis CU1 was not resistant to any of these antibiotics above defined regulatory thresholds, based upon comparison of the measured MICs with the microbiological cut-off values listed by EFSA for the Bacillus species (EFSA, 2012). B. subtilis CU1 was also evaluated for phenotypic evidence of toxigenic activity using three validated in vitro assays and the results of all tests for hemolytic and cytotoxic activity as well as biosurfactant production consistently demonstrated a lack of toxigenicity. As outlined in the safety decision tree proposed by Pariza et al. (2015) , an important and necessary step in the safety assessment of novel microbial cultures is to sequence the genome of the new microbial strain, which can then be bioinformatically searched for genetic factors associated with pathogenicity as well Table 6 Summary of all adverse events by intensity. as antibiotic resistance. In fact, the B. subtilis CU1 genome was sequenced and BLAST software was employed to survey the genome for genes associated with conferring antibiotic or multidrug resistance, as well as genes implicated in biogenic amine (i.e., histamine, tryptamine) or enterotoxin (i.e., cytotoxin, haemolysin) production. Overall, no genetic factors associated with antibiotic or multidrug resistance as well as biogenic amine or enterotoxin synthesis were identified in the B. subtilis CU1 genome (personal data), confirming the results of the above in vitro assays. Therefore, based upon the results of the genomic, antimicrobial, and cytotoxic activity assays, B. subtilis CU1 was concluded to be adequately characterized and was concluded to be a non-toxigenic strain of B. subtilis. These measures also satisfy the QPS requirements outlined by EFSA for members of the Bacillus species (EFSA, 2015) . In the human study, the daily consumption of B. subtilis CU1 (2 Â 10 9 spores/day) for 40 days over 16 weeks was found to be safe and well-tolerated by elderly subjects. B. subtilis CU1 was not associated with the occurrence of adverse events, both related and unrelated to treatment, when compared to the placebo group. Consumption of B. subtilis CU1 was also found to have no effect on any of the biological safety parameters assessed, and overall, was safe and well-tolerated by all subjects. The lack of toxicity observed with B. subtilis CU1 is consistent with the fact that the B. subtilis species is associated with a long history of safe consumption as both a dietary supplement and food ingredient in different parts of the world (Cutting, 2011; Shurtleff, 2012) . To date, the consumption of various strains of B. subtilis by humans has primarily been through the intake of probiotic mixtures marketed as dietary supplements in Asia, Europe, and the U.S. For example, the probiotic preparation Medilac ® containing B. subtilis R0179 combined with Enterococcus faecium R0026 has been marketed in Korea since 1994 and in China since 2000 (Tompkins et al., 2010; Dion, 2012) . Standard preparations contain a nine to one ratio of E. faecium R0026 to B. subtilis R0179, and when taken three times per day, a total of approximately 3.0 Â 10 8 CFU of B. subtilis are ingested per day. A number of post-market clinical studies have been conducted on this preparation that consistently indicate that consumption of B. subtilis R0179 is not associated with any toxicological responses or adverse reactions in humans (Tompkins et al., 2010) . B. subtilis is also associated with a long history of safe use in the food industry, primarily the consumption of fermented food products in the Asian and African regions. In Japan, proprietary variants of B. subtilis have been consumed for decades as a component of the fermented food product natto. This traditional food is prepared by fermenting soybeans with B. subtilis and is believed to have been a component of the Japanese diet as early as the year 1450 (Shurtleff, 2012) . Natto products carry up to 10 8 viable spores of B. subtilis per gram of product, and its consumption has been associated with a long history of safe use and beneficial health effects (Cutting, 2011) . Other alkaline-fermented foods generated by bacterial cultures containing B. subtilis, such as Thai thua-nao and kinema from cooked soybeans, dawadawa from African locust beans, ugba from African oil beans, and ogiri from melon seeds, are safely consumed in a number of African and Southeast Asian countries (Wang and Fung, 1996) . B. subtilis also has a long history of safe use in food enzyme manufacturing and is one of the most widely employed bacterial species for this application (Schallmey et al., 2004) .
Interestingly, recent evidence suggests that even in the absence of consuming food products or dietary supplements that contain B. subtilis, humans are inherently exposed to this microbe. For instance, B. subtilis spores have been detected in the gastrointestinal tract and feces of humans that have not intentionally consumed B. subtilis-containing food products or dietary supplements (Tam et al., 2006; Hong et al., 2009) . Fakhry et al. (2008) isolated spore-forming bacteria from the feces and ileal biopsies of healthy non-probiotic consuming human volunteers, and of the 25 Bacillus strains isolated, 13 of them were found to belong to the B. subtilis species. Similarly, Hong et al. (2009) have identified and characterized a diverse population of B. subtilis strains residing within the human gastrointestinal tract. It has been hypothesized that B. subtilis has been introduced to the human gastrointestinal tract through the ingestion of plant matter, as these spores inhabit the upper layers of the soil in great abundance and could become an intestinal commensal. Nevertheless, from a safety perspective, whether exposure occurs due to direct or indirect consumption, any bacteria entering the small and large intestines (viable or dead) are not expected to translocate into the systemic circulation, as the gastrointestinal mucosa is impermeable to bacteria in healthy individuals. Studies in animals specifically investigating the fate and dissemination of B. subtilis spores in vivo have demonstrated that B. subtilis spores administered orally do not appear to cross mucosal surfaces and are in fact excreted in the feces (Hoa et al., 2001; Duc et al., 2003) .
Conclusion
The safety of B. subtilis CU1 (CNCM I-2745), a probiotic intended for human consumption, was evaluated by conducting a series of in vitro and clinical investigations. Genomic characterization using 16S rDNA and gyrB sequencing confirmed the identity of the organism as under the species B. subtilis, and classification at the subspecies level as Bacillus subtilis subspecies spizizenii was suggested by the greatest gyrB sequence homology observed with B. subtilis subsp. spizizenii isolates. Genomic analyses using RAPD PCR and PFGE were used to further characterize the probiotic at the strain level. In vitro investigations demonstrated that antibiotic resistance was not observed at levels exceeding the regulatory cutoffs set by EFSA and that B. subtilis CU1 was absent of toxigenic activity. Repeated consumption of B. subtilis CU1 spores was demonstrated to be safe and did not induce any undesirable physiological effects or biological safety concerns in adult subjects consuming 2 Â 10 9 spores/day for 40 days in total. Based on these results and on information supporting the long history of safe consumption of B. subtilis in the diet, we conclude that B. subtilis CU1 is safe for human consumption.
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